Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066710 · ClinicalTrials.gov registry record · Early Phase 1
Propranolol in Primary Progressive Aphasia
A Early Phase 1 study of Aphasia, Primary Progressive, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06066710 is a Early Phase 1 study of Aphasia, Primary Progressive that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06066710, a Early Phase 1 study of Aphasia, Primary Progressive, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Propranolol
- DEVICE Magnetic Resonance Imaging (MRI)
Study Locations (1)
Missouri
- University of Missouri-Columbia - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06066710
The ClinicalTrials.gov registry entry for NCT06066710 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aphasia, Primary Progressive appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06066710 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06066710 about?
NCT06066710 is a clinical study titled "Propranolol in Primary Progressive Aphasia". The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure....
What is the current status of trial NCT06066710?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-01-13. Estimated completion is 2027-12.
What conditions does trial NCT06066710 study?
This clinical trial studies the following conditions: Aphasia, Primary Progressive.
What interventions are being tested in trial NCT06066710?
The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG), Magnetic Resonance Imaging (MRI) (DEVICE).
Who is sponsoring clinical trial NCT06066710?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066710 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aphasia, Primary Progressive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.